Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease

No abstract is available for this paper.

• Publication year

  2017

• Venue

  European Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2017-07-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00259-017-3778-1PMID 28733764
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• UvA-DARE ( Digital Academic Repository ) 123 I-mIBG assessed cardiac sympathetic activity : standardizing towards clinical implementation

  2017cited by this paper
• A unique association of arrhythmogenic right ventricular dysplasia and acute myocarditis, as assessed by cardiac MRI: a case report

  2016cited by this paper
• Myocardial 123I-mIBG scintigraphy in relation to markers of inflammation and long-term clinical outcome in patients with stable chronic heart failure

  2016cited by this paper
• Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by 123I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease

  2016influential reference
• Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR

  2016cited by this paper
• Focal Reduction in Cardiac 123I-Metaiodobenzylguanidine Uptake in Patients With Anderson-Fabry Disease.

  2016cited by this paper
• First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease

  2015cited by this paper
• Fabry disease.

  2015cited by this paper
• Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance

  2014influential reference
• Observer reproducibility of results from a low-dose 123I-metaiodobenzylguanidine cardiac imaging protocol in patients with heart failure

  2013cited by this paper
• The prognostic role of late gadolinium enhancement magnetic resonance imaging in patients with cardiomyopathy.

  2013cited by this paper
• Small fibre neuropathy in Fabry disease

  2013cited by this paper
• Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping

  2013influential reference
• Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease.

  2013influential reference
• Fibrosis: a key feature of Fabry disease with potential therapeutic implications

  2013influential reference
• Autonomic nervous system activity in patients with Fabry disease

  2012cited by this paper
• Cardiovascular magnetic resonance of myocardial edema using a short inversion time inversion recovery (STIR) black-blood technique: Diagnostic accuracy of visual and semi-quantitative assessment

  2012cited by this paper
• Assessment of myocardial fibrosis with cardiovascular magnetic resonance.

  2011cited by this paper
• Electrocardiographic changes in early recognition of Fabry disease

  2011cited by this paper
• Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment.

  2011cited by this paper
• Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology

  2010cited by this paper
• Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy.

  2009cited by this paper
• Late Gadolinium Enhancement by Cardiovascular Magnetic Resonance Heralds an Adverse Prognosis in Nonischemic Cardiomyopathy

  2009cited by this paper
• Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

  2009cited by this paper
• Fabry disease.

  2009cited by this paper
• Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy.

  2008cited by this paper
• Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.

  2007cited by this paper
• The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease.

  2006cited by this paper
• Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

  2003cited by this paper
• Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

  2002cited by this paper
• Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

  2002cited by this paper
• α-Galactosidase A deficiency. Fabry disease

  2001cited by this paper
• The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction.

  2000cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper
• Chest pain in cardiac-transplant recipients. Evidence of sensory reinnervation after cardiac transplantation.

  1991cited by this paper
• Scintigraphic assessment of sympathetic innervation after transmural versus nontransmural myocardial infarction.

  1991cited by this paper
• Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy.

  1990cited by this paper
• Cardiac sympathetic imaging with radioiodinated metaiodobenzylguanidine (MIBG)

  1990cited by this paper
• Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine.

  1989cited by this paper
• Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants.

  1989cited by this paper
• Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy.

  1988cited by this paper
• Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy.

  1988cited by this paper
• Transmural Myocardial Infarction in the Dog Produces Sympathectomy in Noninfarcted Myocardium

  1983cited by this paper
• Myocardial imaging with a radioiodinated norepinephrine storage analog.

  1981cited by this paper
• Myocardial imaging in man with I-123 meta-iodobenzylguanidine.

  1981cited by this paper

• Fabry Disease Cardiomyopathy: A Practical Guide for Cardiologists.

  2026cites this paper
• Unveiling Functional Impairment in Fabry Disease: The Role of Peripheral vs. Cardiac Mechanisms

  2025cites this paper
• Cardiac involvement in Anderson–Fabry disease. The role of advanced echocardiography

  2024cites this paper
• Contemporary Multimodality Imaging for Diagnosis and Management of Fabry Cardiomyopathy

  2024cites this paper
• Biomarkers in anderson-Fabry disease: what should we use in the clinical practice?

  2024cites this paper
• A chalcone-based ESIPT and AIE fluorophore for β-gal imaging in living cells.

  2024cites this paper
• Visualized Enzyme-Activated Fluorescence Probe for Accurately Detecting β-Gal in Living Cells and BALB/c Nude Mice

  2024cites this paper
• Circulating mitochondria carrying cGAS promote endothelial Secreted group IIA phospholipase A2-mediated neuroinflammation through activating astroglial/microglial Integrin-alphavbeta3 in subfornical organ to augment central sympathetic overdrive in heart failure rats.

  2024cites this paper
• Dual-Signal Triple-Mode Optical Sensing Platform for Assisting in the Diagnosis of Kidney Disorders.

  2023cites this paper
• β-galactosidase activity monitoring and bioimaging by a novel ICT mechanism-based NIR fluorescent probe with large Stokes shift

  2023cites this paper
• Role of Imaging in Cardiomyopathies

  2023cites this paper
• Impairment of sympathetic activity in Fabry disease cardiomyopathy: A further challenge for cardiac imaging

  2023cites this paper
• Detection of sympathetic denervation defects in Fabry disease by hybrid [11C]meta-hydroxyephedrine positron emission tomography and cardiac magnetic resonance

  2023cites this paper
• Multimodality Cardiac Imaging in Cardiomyopathies: From Diagnosis to Prognosis

  2022cites this paper
• Multimodality Imaging in Cardiomyopathies with Hypertrophic Phenotypes

  2022cites this paper
• A new near-infrared excitation/emission fluorescent probe for the detection of β-galactosidase in living cells and in vivo.

  2022cites this paper
• Fabry Disease and the Heart: A Comprehensive Review

  2021cites this paper
• New insights into the detection mechanism of β-galactosidase in living cells with fluorescent probes

  2021cites this paper
• Cardiac Imaging in Anderson-Fabry Disease: Past, Present and Future

  2021cites this paper
• A near-infrared fluorescent probe for monitoring and imaging of β-galactosidase in living cells.

  2020cites this paper
• Multimodality imaging approach to Fabry cardiomyopathy: Any role for nuclear cardiology?

  2020cites this paper
• Fabry disease pain: patient and preclinical parallels

  2020cites this paper
• Myocardial ischaemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options

  2020cites this paper
• Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative

  2020cites this paper
• Focal reduction in left ventricular 123I-metaiodobenzylguanidine uptake and impairment in systolic function in patients with Anderson-Fabry disease

  2019cites this paper
• New insights for early assessment of cardiac involvement in Anderson-Fabry disease

  2019cites this paper
• A hemicyanine-based colorimetric turn-on fluorescent probe for β-galactosidase activity detection and application in living cells

  2019cites this paper
• Multimodality Imaging Assessment of Fabry Disease.

  2019cites this paper
• Potential prognostic implications of myocardial thallium-201 and iodine-123-beta-methylpentadecanoic acid dual scintigraphy in patients with Anderson–Fabry disease

  2019cites this paper
• Left Ventricular Mass in Hypertrophic Cardiomyopathy Assessed by 2D-Echocardiography: Validation with Magnetic Resonance Imaging

  2019cites this paper
• Behind Traditional Semi-quantitative Scores of Myocardial Perfusion Imaging: An Eye on Niche Parameters

  2019cites this paper
• Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying &agr;-Galactosidase A Mutation: Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-Tracking Echocardiography

  2018cites this paper
• Diagnosis and treatment of the cardiovascular consequences of Fabry disease

  2018cites this paper
• Il dolore nella Malattia di Fabry

  2018cites this paper
• Multimodality imaging in Fabry cardiomyopathy: from early diagnosis to therapeutic targets

  2018cites this paper
• SPECT vs. PET in cardiac innervation imaging: clash of the titans

  2018cites this paper
• Cardiac amyloidosis: A new challenge of multimodality imaging

  2018cites this paper